Can a $10 arthritis pill tame rare blood cancers?

NCT ID NCT06541249

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests low-dose methotrexate, a common arthritis drug, in 54 people with three rare blood cancers: polycythemia vera, essential thrombocythemia, and myelofibrosis. Researchers want to see if it can shrink spleens, improve symptoms, and lower blood counts safely. If successful, it could provide an affordable treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Methotrexate (low-dose, once weekly by mouth)
What this could lead to: If it works, this could offer a safe, inexpensive treatment option for blood cancers like myelofibrosis, especially for patients who cannot afford newer drugs.
What could go wrong: This is a small, early-phase trial (54 people) testing a drug already used for other conditions. It may not show enough benefit or could cause side effects like liver or lung problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA (ET) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL THROMBOCYTHEMIA (ET) MYELOFIBROSIS，MF POLYCYTHEMIA VERA (PV)

Contacts and locations

Locations

Ruttenberg Treatment Center
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.